%20-%20No%20Text.png)
%20-%20No%20Text.png)
Wealth is best enjoyed in good health
Financial planning ensures your wealth works for you, while a proactive approach to health helps you make the most of it.
By adopting positive lifestyle choices and building sustainable health habits, you can support your wellbeing and embrace a better quality of life – now and in the years ahead.
Exclusive partnership between Manulife & Guardant Health
As part of our commitment to your wellbeing and supporting you in early detection, we have partnered with Guardant Health - a global leader in blood-based cancer testing, with over a decade of experience1.
This exclusive partnership makes us the first insurer across Singapore, Hong Kong and the Philippines to offer a multi-cancer screening test.
Through this collaboration, you have the opportunity to access the Multi-Cancer Detection (MCD)* test when you purchase a qualifying plan today.
For more information, please click here.
Here’s how you can access the Multi-Cancer Detection (MCD)* test
1. Speak with a Manulife Financial Representative on your financial needs
2. Purchase a suitable plan
3. Eligible customers receive a complimentary Multi-Cancer Detection (MCD) test* worth up to SGD 2,000. Terms and conditions apply.
Start today and plan ahead with confidence – for both your health and your wealth.
Thank you for contacting Manulife Singapore!
Our Financial Consultant will be in touch with you soon.
Here are some links you might find useful.
Consent
By submitting your personal details,
- You acknowledge that you authorise and consent to Manulife (Singapore) Pte Ltd ("Manulife) (including employees and Representatives of Manulife) to collect, use, disclose and retain your personal data for the purpose of receiving notifications via SMS(es) and email(s) to service your request; and
- You consent to Manulife to contact you (even though your telephone number may be already registered on the National Do Not Call Registry) for marketing purposes, and to provide you with marketing, advertising and promotional information, materials and/or documents relating to financial advisory services and products distributed by Manulife, if applicable.
The consent you provide is in addition to and does not supersede, vary or nullify any consent which you may have provided previously in respect of the above purposes, unless your previous consent has been withdrawn.
You also confirm that you are the user and/or subscriber of the telephone number and email address provided by you.
About Guardant Health
Guardant Health is a global leader in blood‑based cancer testing, with more than a decade of experience¹. The company has demonstrated strong scientific rigour, supported by over 600 peer‑reviewed publications¹, and pioneered blood‑based cancer testing with the first FDA‑approved liquid Comprehensive Genomic Profiling (CGP) test for all advanced solid tumours, alongside continued innovation reflected in more than 800 issued patents and patent applications3.
Important information
* Your clinical eligibility will be determined by the medical provider with whom you will schedule your appointment.
Sources:
1. Data on file. Guardant Health, Inc. Sep, 2025.
2. The US FDA Breakthrough Device designation referenced includes eight cancer types – bladder, colorectal, esophageal, gastric, liver, lung, ovarian, and pancreatic cancer. Source: Guardant Health. FDA Grants Breakthrough Device Designation to Guardant Health’s Multi-Cancer Detection (MCD) Test. Published June 3, 2025.
3. Guardant Health Investor Day 2025 Presentation.
